News & Events – Page 2 – Sumitovant

Select Company

April 12, 2021Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
March 29, 2021Sumitovant Biopharma Completes Acquisition of Urovant Sciences
February 12, 2021Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
February 11, 2021Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
December 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
November 24, 2020Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 12, 2020Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
October 07, 2020Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
August 13, 2020Urovant Sciences Reports Fiscal First Quarter 2020 Results
June 18, 2020Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
« Previous 1 2 3 4 … 7 Next »